News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
519,076 Results
Type
Article (35592)
Company Profile (67)
Press Release (483417)
Multimedia
Podcasts (39)
Webinars (11)
Section
Business (146148)
Career Advice (2375)
Deals (26598)
Drug Delivery (92)
Drug Development (70327)
Employer Resources (135)
FDA (13044)
Job Trends (11588)
News (260675)
Policy (25739)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (1)
2024 BioMidwest Standard (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (6)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (2412)
Accelerated approval (5)
Adcomms (26)
Allergies (72)
Alliances (36389)
ALS (84)
Alzheimer's disease (1358)
Antibody-drug conjugate (ADC) (114)
Approvals (13046)
Artificial intelligence (220)
Autoimmune disease (22)
Automation (14)
Bankruptcy (301)
Best Places to Work (9515)
BIOSECURE Act (13)
Biosimilars (87)
Biotechnology (56)
Bladder cancer (61)
Brain cancer (24)
Breast cancer (239)
Cancer (1884)
Cardiovascular disease (172)
Career advice (1994)
Career pathing (31)
CAR-T (127)
Cell therapy (360)
Cervical cancer (16)
Clinical research (57386)
Collaboration (647)
Compensation (216)
Complete response letters (20)
COVID-19 (2357)
CRISPR (35)
C-suite (230)
Cystic fibrosis (74)
Data (1928)
Decentralized trials (2)
Denatured (6)
Depression (47)
Diabetes (237)
Diagnostics (5487)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (106)
Drug pricing (87)
Drug shortages (22)
Duchenne muscular dystrophy (86)
Earnings (53130)
Editorial (35)
Employer branding (17)
Employer resources (123)
Events (70604)
Executive appointments (677)
FDA (14087)
Featured Employer (21)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (614)
Gene editing (88)
Generative AI (18)
Gene therapy (275)
GLP-1 (664)
Government (3978)
Grass and pollen (4)
Guidances (48)
Healthcare (15346)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (114)
Indications (24)
Infectious disease (2488)
Inflammatory bowel disease (121)
Inflation Reduction Act (8)
Influenza (44)
Intellectual property (77)
Interviews (517)
IPO (12017)
IRA (41)
Job creations (2421)
Job search strategy (1632)
Kidney cancer (10)
Labor market (17)
Layoffs (397)
Leadership (20)
Legal (5376)
Liver cancer (68)
Lung cancer (296)
Lymphoma (126)
Machine learning (5)
Management (51)
Manufacturing (227)
MASH (68)
Medical device (10171)
Medtech (10175)
Mergers & acquisitions (15019)
Metabolic disorders (619)
Multiple sclerosis (70)
NASH (22)
Neurodegenerative disease (93)
Neuropsychiatric disorders (28)
Neuroscience (1859)
NextGen: Class of 2025 (5216)
Non-profit (3789)
Northern California (2018)
Now hiring (30)
Obesity (322)
Opinion (202)
Ovarian cancer (61)
Pain (79)
Pancreatic cancer (72)
Parkinson's disease (138)
Partnered (17)
Patents (198)
Patient recruitment (90)
Peanut (39)
People (49175)
Pharmaceutical (22)
Pharmacy benefit managers (9)
Phase I (17658)
Phase II (25277)
Phase III (19308)
Pipeline (1058)
Policy (117)
Postmarket research (2196)
Preclinical (7077)
Press Release (53)
Prostate cancer (85)
Psychedelics (37)
Radiopharmaceuticals (203)
Rare diseases (331)
Real estate (3804)
Recruiting (51)
Regulatory (18235)
Reports (25)
Research institute (1991)
Resumes & cover letters (343)
Rett syndrome (4)
RNA editing (2)
RSV (37)
Schizophrenia (70)
Series A (110)
Series B (68)
Service/supplier (2)
Sickle cell disease (49)
Southern California (1780)
Special edition (10)
Spinal muscular atrophy (143)
Sponsored (25)
Startups (2531)
State (2)
Stomach cancer (14)
Supply chain (51)
Tariffs (17)
The Weekly (32)
United States (17392)
Vaccines (588)
Venture capitalists (25)
Weight loss (218)
Women's health (24)
Worklife (16)
Date
Last 7 days (390)
Last 30 days (1812)
Last 365 days (27413)
2025 (7694)
2024 (29334)
2023 (33025)
2022 (43268)
2021 (46246)
2020 (44751)
2019 (38058)
2018 (28839)
2017 (25867)
2016 (24457)
2015 (28631)
2014 (21271)
2013 (17137)
2012 (18309)
2011 (19387)
2010 (17118)
Location
Africa (682)
Alabama (46)
Alaska (4)
Arizona (138)
Arkansas (11)
Asia (32128)
Australia (6824)
California (4570)
Canada (1696)
China (430)
Colorado (203)
Connecticut (196)
Delaware (119)
Europe (71333)
Florida (746)
Georgia (161)
Idaho (43)
Illinois (418)
India (21)
Indiana (245)
Iowa (5)
Japan (131)
Kansas (83)
Kentucky (17)
Louisiana (6)
Maine (49)
Maryland (735)
Massachusetts (3176)
Michigan (185)
Minnesota (277)
Mississippi (1)
Missouri (71)
Montana (20)
Nebraska (22)
Nevada (53)
New Hampshire (60)
New Jersey (1387)
New Mexico (20)
New York (1331)
North Carolina (729)
North Dakota (5)
Northern California (2018)
Ohio (151)
Oklahoma (5)
Oregon (22)
Pennsylvania (1014)
Puerto Rico (11)
Rhode Island (23)
South America (939)
South Carolina (15)
South Dakota (1)
Southern California (1780)
Tennessee (77)
Texas (697)
Utah (152)
Virginia (120)
Washington D.C. (47)
Washington State (440)
West Virginia (3)
Wisconsin (37)
519,076 Results for "oncoinvent as".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025
·
2 min read
Press Releases
Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities
December 4, 2024
·
2 min read
Press Releases
Oncoinvent to Present at JonesTrading Virtual Radiopharma Day
October 28, 2024
·
1 min read
FDA
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer
Oncoinvent Receives FDA Fast Track Designation for Radspherin ® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer.
June 24, 2024
·
3 min read
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
Oncoinvent AS today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.
May 15, 2024
·
2 min read
Press Releases
Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses
November 11, 2024
·
5 min read
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
February 21, 2024
·
2 min read
Business
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
Oncoinvent AS announced the appointment of newly elected members of its Board of Directors and the formation of a Scientific and Clinical Advisory Board under the leadership of founding scientists Roy Larsen and Øyvind Bruland, previous board members and leading experts in oncology and pharmaceutical development.
April 2, 2024
·
6 min read
Press Releases
Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients
October 10, 2024
·
3 min read
Press Releases
Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of Radspherin® in Colorectal Cancer
November 1, 2024
·
3 min read
1 of 51,908
Next
